|
EMA Posts Biosimilars Q&A to Help Clarify Presubmission Meetings
The European Medicines Agency (EMA) has published question-and-answer guidance on marketing applications for biosimilars, providing advice on a number of pre-submission issues, such as requesting an accelerated assessment, and giving detailed answers about review timing.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives